Conversely, when a patient has a high level of VEGF and a low ERLBA concentration, tamoxifen could fail to contrast the tumour's metastatic potential and more tailored adjuvant treatment would be required including, for example, an antiangiogenic agent. Here, VEGFA is linked to neoplasm.